Notice for leniolisib (Ballia Holdings Pty Ltd)
Active ingredients
leniolisib
Sponsor
Date of review outcome
Lapse date
Type
Priority review
Indication
Treatment of activated phosphoinositide 3-kinase delta syndrome (APDS) in adults and adolescents 12 years of age or older
Therapeutic area
Immunology